UNSPSC 51334201: Clorotepine

This classification denotes a dopamine antagonist with the molecular formula C19H21ClN2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E65W20MU7A, chemically known as 1-(8-chloro-10,11-dihydrodibenzo(b,f)thiepin-10-yl)-4-methylpiperazine but generally known as clorotepine, which bears US NIH Compound Identifier 1238. European Medicines Agency schedules Clorotepine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06765MIG. The term CLOROTEPINE is an International Non-Proprietary Name.

UNSPSC 51334201 Clorotepine is a Commodity code that captures pharmaceutical procurement by state and local health authorities, though recent solicitations under this code show minimal direct correlation to clorotepine specifically. Instead, state and local buyers are pursuing naloxone, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs. Seminole County, Florida, a county health authority, is seeking 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually through an IFB with quarterly deliveries to its Community Health Building. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), a state-level cooperative purchasing vehicle administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products with product distribution through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson). The Texas Health and Human Services Commission, a state agency, posted an RFI to explore direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements. These solicitations signal state and local movement toward cost-containment strategies, opioid-use mitigation initiatives, and alternative pharmaceutical supply models rather than procurement of a single drug.

The code shows recent activity across Florida, Texas, and the multistate MMCAP region (Minnesota and Oregon). The Seminole County IFB (Solicitation IFB60459723LAS) closed July 26, 2023, with electronic submission required and a two-year initial contract term plus one-year renewal option. The MMCAP RFP (S1070000015802) closed March 26, 2026, with contract performance to begin July 1, 2026; awards will be multi-vendor based on therapeutic considerations and product availability, with vendor compliance measured against fixed pricing (10 percent weighted), price competitiveness (75 percent), and EDI capability (5 percent). The Texas RFI (HHS0017013, closed April 3, 2026) is exploratory, designed to gather market intelligence before formal procurement and does not carry binding timelines or award values. Vendors pursuing this code should expect cGMP and DSCSA compliance requirements, E-Verify authorization, commercial general liability insurance of $5 million, and performance penalties for late reporting or improper fulfillment in multistate cooperative arrangements.